Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $34187.0.

  • BioNexus Gene Lab's Cash from Financing Activities rose 16106.78% to $34187.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $30910.0, marking a year-over-year decrease of 9544.16%. This contributed to the annual value of $144975.0 for FY2024, which is 9768.96% down from last year.
  • Latest data reveals that BioNexus Gene Lab reported Cash from Financing Activities of $34187.0 as of Q3 2025, which was up 16106.78% from -$1030.0 recorded in Q2 2025.
  • BioNexus Gene Lab's 5-year Cash from Financing Activities high stood at $5.7 million for Q3 2023, and its period low was -$55982.0 during Q3 2024.
  • Its 5-year average for Cash from Financing Activities is $362897.6, with a median of -$1561.5 in 2022.
  • In the last 5 years, BioNexus Gene Lab's Cash from Financing Activities crashed by 37817.93% in 2021 and then surged by 33117246.54% in 2023.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Cash from Financing Activities stood at -$4959.0 in 2021, then surged by 54.16% to -$2273.0 in 2022, then surged by 23493.44% to $531733.0 in 2023, then crashed by 100.26% to -$1387.0 in 2024, then soared by 2564.82% to $34187.0 in 2025.
  • Its Cash from Financing Activities stands at $34187.0 for Q3 2025, versus -$1030.0 for Q2 2025 and -$860.0 for Q1 2025.